Tumour angiogenesis: an elusive target in castration-resistant prostate cancer
Mené sur 1 224 patients atteints d'un cancer métastatique de la prostate résistant à la castration, cet essai international de phase III évalue, du point de vue de la survie globale, l'ajout de l'aflibercept à une combinaison docétaxel et prednisone en traitement de première ligne
Although initially met with scepticism, the idea of tumour angiogenesis is now accepted as a hallmark of cancer and has been explored as a therapeutic target in almost every type of neoplastic disease, including prostate cancer. In The Lancet Oncology, Ian Tannock and colleagues report the results of the VENICE trial, a randomised phase 3 trial of docetaxel plus prednisone with or without the soluble VEGF decoy receptor, aflibercept, in patients with castration-resistant prostate cancer...
The Lancet Oncology , commentaire, 2012